Literature DB >> 17906920

Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects.

David Czock1, Frieder Keller.   

Abstract

Mathematical modeling of drug effects maximizes the information gained from an experiment, provides further insight into the mechanisms of drug effects, and allows for simulations in order to design studies or even to derive clinical treatment strategies. We reviewed modeling of antimicrobial drug effects and show that most of the published mathematical models can be derived from one common mechanism-based PK-PD model premised on cell growth and cell killing processes. The general sigmoid Emax model applies to cell killing and the various parameters can be related to common pharmacodynamics, which enabled us to synthesize and compare the different parameter estimates for a total of 24 antimicrobial drugs from published literature. Furthermore, the common model allows the parameters of these models to be related to the MIC and to a common set of PK-PD indices. Theoretically, a high Hill coefficient and a low maximum kill rate indicate so-called time-dependent antimicrobial effects, whereas a low Hill coefficient and a high maximum kill rate indicate so-called concentration-dependent effects, as illustrated in the garenoxacin and meropenem examples. Finally, a new equation predicting the time to microorganism eradication after repeated drug doses was derived that is based on the area under the kill-rate curve.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906920     DOI: 10.1007/s10928-007-9069-x

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.410


  60 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 2.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

Authors:  J W Mouton; A A Vinks; N C Punt
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

4.  Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains.

Authors:  Wanchai Treyaprasert; Stephan Schmidt; Kenneth H Rand; Uthai Suvanakoot; Hartmut Derendorf
Journal:  Int J Antimicrob Agents       Date:  2006-12-27       Impact factor: 5.283

5.  Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

Authors:  Paul G Ambrose; Sujata M Bhavnani; Christopher M Rubino; Arnold Louie; Tawanda Gumbo; Alan Forrest; George L Drusano
Journal:  Clin Infect Dis       Date:  2006-11-27       Impact factor: 9.079

6.  Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.

Authors:  Ping Liu; Kenneth H Rand; Bernd Obermann; Hartmut Derendorf
Journal:  Int J Antimicrob Agents       Date:  2005-02       Impact factor: 5.283

Review 7.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

8.  Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).

Authors:  Eric Viaene; Hugues Chanteux; Hélène Servais; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  In vivo pharmacodynamic activity of daptomycin.

Authors:  Nasia Safdar; David Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  A new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations.

Authors:  Michael Nikolaou; Vincent H Tam
Journal:  J Math Biol       Date:  2005-09-29       Impact factor: 2.164

View more
  45 in total

Review 1.  Drug therapy in patients with chronic renal failure.

Authors:  Bertram Hartmann; David Czock; Frieder Keller
Journal:  Dtsch Arztebl Int       Date:  2010-09-17       Impact factor: 5.594

2.  Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.

Authors:  Jürgen B Bulitta; Neang S Ly; Cornelia B Landersdorfer; Nicholin A Wanigaratne; Tony Velkov; Rajbharan Yadav; Antonio Oliver; Lisandra Martin; Beom Soo Shin; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Authors:  Katherine Winter; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

4.  Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

5.  Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.

Authors:  Soon-Ee Cheah; Jian Li; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

6.  Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

7.  Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium.

Authors:  Bruna Kochhann Menezes; Izabel Almeida Alves; Keli Jaqueline Staudt; Betina Montanari Beltrame; Letícia Venz; Lessandra Michelin; Bibiana Verlindo Araujo; Leandro Tasso
Journal:  Braz J Microbiol       Date:  2019-12-16       Impact factor: 2.476

Review 8.  Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs.

Authors:  Julie A Simpson; Sophie Zaloumis; Alysha M DeLivera; Ric N Price; James M McCaw
Journal:  AAPS J       Date:  2014-07-24       Impact factor: 4.009

9.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

10.  Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.

Authors:  Goue Denis Gohore Bi; Jun Li; Fahima Nekka
Journal:  Theor Biol Med Model       Date:  2009-06-26       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.